10 Phase IV: Therapeutic Use
Phase IV encompasses all clinical studies conducted after a drug has received regulatory approval. These studies serve multiple purposes, from satisfying regulatory requirements to expanding the understanding of the drug’s benefits and risks in broader patient populations.
Once a drug is approved and marketed, it enters a new phase of its lifecycle. The controlled conditions of clinical trials give way to real-world clinical practice, where patients may differ from those studied in trials, where adherence patterns vary, and where the drug is used alongside other medications and in combination with diverse health conditions.
This transition from the controlled environment of clinical trials to the complexity of clinical practice represents both an opportunity and a responsibility. The opportunity lies in learning how the drug performs in the broader population for whom it is intended. The responsibility lies in continuing to monitor safety and to generate evidence that helps clinicians and patients make informed treatment decisions.
10.1 Types of Phase IV Studies
Phase IV studies can be broadly categorized by their primary purpose (see Table 10.1):
| Study Type | Purpose | Examples | Regulatory Status |
|---|---|---|---|
| Post-Marketing Safety | Detect rare or delayed adverse events | Long-term safety studies, special population studies | May be required or voluntary |
| Post-Marketing Efficacy | Evaluate real-world effectiveness | Subpopulation analyses, comparative effectiveness | Usually voluntary |
| Post-Marketing Commitments (PMC) | Fulfill regulatory requirements | Confirmatory trials for accelerated approval | Required as condition of approval |
| Label Extension | Expand approved uses | Pediatric studies, new indication trials | Required for new indication claims |
| Outcomes Research | Demonstrate value in real-world practice | Quality of life studies, health economics | Usually voluntary; payer-driven |
Post-marketing safety studies aim to detect adverse events that may not have been identified in premarketing trials, either because they are rare, because they emerge only with prolonged exposure, or because they occur preferentially in populations not well represented in the original trials.
Post-marketing efficacy studies may be conducted to evaluate the drug’s performance in specific subpopulations, to compare its effectiveness to other treatments under real-world conditions, or to demonstrate effects on long-term outcomes that could not be assessed in the time frame of premarketing trials.
Post-marketing commitment studies are those required by regulatory agencies as a condition of approval. These may include studies to confirm efficacy when approval was based on a surrogate endpoint (as in accelerated approval), to evaluate safety in specific populations of concern, or to assess effects on outcomes not fully evaluated before approval.
In addition, sponsors may conduct studies to support label extensions, seeking approval for new indications, new populations (such as pediatric patients), or new dosing regimens.
This is particularly critical given the historical “pediatric labeling gap.” The FDA has tracked pediatric labeling changes under federal laws including the Best Pharmaceuticals for Children Act (BPCA), the Pediatric Research Equity Act (PREA), and the Pediatric Rule since 1998 (U.S. Food and Drug Administration 2025). These legislative initiatives have significantly improved pediatric labeling over the past two decades, with hundreds of labeling changes approved to provide evidence-based dosing and safety information for pediatric populations. However, the “therapeutic orphan” problem—where drugs are used in children without adequate pediatric studies—remains a primary driver for dedicated Phase IV pediatric programs.
10.2 Pharmacovigilance
The limitations of spontaneous reporting—including underreporting, uncertain causality, and lack of denominator data—mean that signals identified through spontaneous reports often require confirmation through formal studies. These may include epidemiologic studies using healthcare databases, registries, or dedicated Phase IV trials.
The volume of safety data processed during the transition from clinical trials to the market is immense. Historical data indicates that on average, one in 30 study subjects per New Drug Application (NDA) will experience a serious adverse event (SAE). For newly approved drugs, approximately 800 SAEs are typically reported to regulatory authorities annually, highlighting the critical need for robust pharmacovigilance systems to filter signal from noise (U.S. Food and Drug Administration 2005).
10.3 Risk Evaluation and Mitigation Strategies
When significant safety concerns are identified, regulatory agencies may require a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval or continued marketing (U.S. Food and Drug Administration 2024). A REMS is a safety strategy designed to manage known or potential serious risks associated with a drug and to enable patients to have continued access to such medicines by managing their safe use.
| REMS Component | Description | Example Application |
|---|---|---|
| Medication Guide | FDA-approved written information for patients about drug risks/benefits | Required with each dispensing; e.g., NSAIDs cardiovascular risk |
| Communication Plan | Ensure healthcare providers receive important safety information | Dear Healthcare Provider letters, professional society communications |
| Elements to Assure Safe Use (ETASU) | Specific requirements for prescribing, dispensing, or receiving | Prescriber certification, patient enrollment, restricted distribution |
| Implementation System | Infrastructure to ensure REMS is executed | Centralized REMS programs with data collection |
| REMS Assessment | Periodic evaluation of REMS effectiveness | Annual or as specified by FDA |
REMS may include any or all of the elements described in Table 10.2. A Medication Guide is written information for patients about the drug’s risks and benefits, required to be provided with each dispensing. Communication Plans ensure that healthcare providers receive important safety information. Elements to Assure Safe Use (ETASU) are specific actions required for prescribing, dispensing, or receiving the drug, and may include special prescriber training and certification, patient enrollment in a registry, or dispensing only through certified pharmacies.
10.4 Comparative Effectiveness Research
Phase IV studies increasingly include comparative effectiveness research (CER), which compares the benefits and harms of different interventions for treating a particular condition. Unlike traditional efficacy trials that compare a drug to placebo under idealized conditions, CER studies are designed to inform real-world clinical decision-making by comparing interventions under conditions that approximate routine practice.
CER studies may be pragmatic clinical trials conducted in real-world settings with broad inclusion criteria and clinically relevant endpoints. They may also be observational studies using data from electronic health records, claims databases, or registries to compare outcomes among patients receiving different treatments in routine clinical care.
10.5 Registries
Patient registries are organized systems that use observational methods to collect uniform data on a population defined by a particular disease, condition, or exposure. Registries can serve multiple Phase IV purposes.
Registries are categorized by their primary focus. Disease registries follow patients with a particular condition to characterize natural history and identify prognostic factors, while product registries—often mandated for drugs with significant safety concerns or accelerated approvals—collect long-term safety and effectiveness data for specific medications. Additionally, pregnancy registries are critical for assessing developmental risks, as they provide the primary source of safety information for a population typically excluded from premarketing trials.
10.6 Real-World Evidence
The concept of real-world evidence (RWE) has gained prominence in recent years. RWE is clinical evidence regarding the usage and potential benefits or risks of a drug derived from analysis of real-world data (RWD)—data relating to patient health status or the delivery of health care routinely collected from electronic health records, claims and billing databases, product and disease registries, and other sources.
Regulatory agencies have shown increasing interest in the potential for RWE to support regulatory decision-making. The FDA’s RWE framework describes how RWE may be used to support approval of new indications for approved drugs and to satisfy post-marketing study requirements. However, the use of RWE for regulatory purposes requires attention to the quality and relevance of the underlying data and to the rigor of the study design and analysis methods.
10.7 Health Technology Assessment (HTA) and Payer Value
While regulatory approval answers the question of whether a drug is safe and effective, it does not answer whether it is worth paying for. This second question is the domain of Health Technology Assessment (HTA) bodies and payers. In many markets, achieving regulatory approval is only the first hurdle. Access to the market depends on demonstrating value.
Cost-effectiveness analysis determines whether the drug provides sufficient health benefit, often measured in Quality-Adjusted Life Years, to justify its price. Bodies like the National Institute for Health and Care Excellence (NICE) in the UK or the Institute for Clinical and Economic Review (ICER) in the US conduct rigorous economic modeling to make this determination. Other bodies, such as IQWiG in Germany, assess whether the new drug offers a proven advantage over the current standard of care—a higher bar than the placebo-controlled evidence often accepted for regulatory approval.
Consequently, Phase IV is frequently the setting for “Real-World Evidence” studies designed specifically to satisfy these payer requirements—collecting data on resource utilization, comparative effectiveness against active controls, and long-term economic outcomes (National Institute for Health and Care Excellence 2022).
10.8 Lifecycle Management
From the sponsor’s perspective, Phase IV is part of a broader lifecycle management strategy for the product. This strategy may include studies to differentiate the product from competitors, to expand into new indications or populations, to optimize dosing, to document comparative effectiveness, or to address safety concerns.
Lifecycle management must balance commercial objectives with scientific integrity. Phase IV studies expand our understanding of drug effects in broader populations, identify rare or delayed adverse effects, and help optimize use in clinical practice. The post-marketing period is a continuation of the learning process, informing evolving clinical guidelines and treatment decisions long after the drug’s initial approval.